methyldopa 500mg tablets
ennogen pharma ltd - methyldopa (anhydrous) - oral tablet - 500mg
day nurse capsules paracetamol 500mg pseudoephedrine hydrochloride 30mg pholcodine 5mg
glaxosmithkline consumer healthcare (ireland) limited - paracetamol; pseudoephedrine hydrochloride; pholcodine - capsule, hard - 500 mg/30 mg/5 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics
lemsip multirelief capsules paracetamol 500mg phenylephrine hydrochloride 6.1mg guaifenesin 100mg
reckitt benckiser ireland ltd - paracetamol; phenylephrine hydrochloride; guaifenesin - capsule, hard - 500 mg/6.1 mg/100 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics
methyldopa 500mg tablets
a a h pharmaceuticals ltd - methyldopa (anhydrous) - oral tablet - 500mg
methyldopa 500mg tablets
the boots company plc - methyldopa (anhydrous) - oral tablet - 500mg
methyldopa 500mg tablets
c p pharmaceuticals ltd - methyldopa (anhydrous) - oral tablet - 500mg
methyldopa 500mg tablets
kent pharma (uk) ltd - methyldopa (anhydrous) - oral tablet - 500mg
methyldopa 500mg tablets
sandoz ltd - methyldopa (anhydrous) - oral tablet - 500mg
methyldopa 500mg tablets
alliance healthcare (distribution) ltd - methyldopa (anhydrous) - oral tablet - 500mg
carbidopa and levodopa tablet
aphena pharma solutions - tennessee, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 25 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial othe